Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 15, 2023

Primary Completion Date

November 15, 2026

Study Completion Date

November 15, 2026

Conditions

AdebrelimabHepatocellular CarcinomaTransformationBevacizumabTACE

Interventions

DRUG

TACE with adebrelimab and bevacizumab

TACE treatment once; Adebrelimab: 20mg/kg, every 3 weeks (21 days); Bevacizumab; 15mg/kg, every 3 weeks (21 days);

Trial Locations (1)

RECRUITING

The First Affiliated Hospital of Xiamen University, Xiamen

All Listed Sponsors

collaborator

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

lead

The First Affiliated Hospital of Xiamen University

OTHER